Interleukin Profiling in Atopic Dermatitis and Chronic Nodular Prurigo
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25158445 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Henning Wiegmann und 4 weiteren Autor:innen. Beteiligte Einrichtung: Section Pruritus Medicine and Center for Chronic Pruritus, Department of Dermatology, University of Muenster, 48149 Muenster, Germany. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Prurigo, Interleukin-13, Interleukins. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Leo Pharma (Germany), LEO Pharma, the DFG Research Unit PruSearch FOR 2690.
Abstract (Originalsprache)
The clinical manifestations of atopic dermatitis (AD) and chronic nodular prurigo (CNPG) include pruritus and eczema/lesions, posing significant challenges for patients. Th2 cells and ILC2, marked by cytokine production—particularly IL-4/13—are crucial therapeutic targets. Despite displaying a dose-dependent lack of pruritus induction post-injection, IL-13 acts through the IL-13Rα1 and IL-13Rα2 receptor system. Our study focused on investigating ex vivo skin biopsies in AD (n = 17), CNPG (n = 14) and healthy controls (HC; n = 10), examining the gene expression landscape of interleukins linked with pruritus (IL-13, IL-4, IL-31) and their corresponding receptors. Compared to HC, results revealed a significant upregulation of IL-4, IL-13, and IL-13RA1 in AD, whereas CNPG did not show increased IL13 expression. Notably, the decoy receptor IL-13RA2 displayed intriguing patterns, with AD showing a marked increase compared to both HC and CNPG. Positive correlations between receptor expression and itch intensity and hyperkinesis sensation underscore clinical relevance, potentially serving as biomarkers. The findings suggest a pivotal role of IL-4 and IL-13, along with IL-13RA1, in pruritus pathogenesis in both entities, while IL-13 upregulation in AD is countered by IL-13RA2. The comparable expression of IL-13RA2 to HC in CNPG suggests the absence of this regulatory mechanism, potentially worsening the disease and leading to prolonged scratching behavior. These insights illuminate the intricate interplay of interleukins and receptors in different pruritus phenotypes, laying the groundwork for understanding underlying mechanisms and offering avenues for therapeutic intervention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Section Pruritus Medicine and Center for Chronic Pruritus, Department of Dermatology, University of Muenster, 48149 Muenster, Germany.
ORCID-Profile: Sonja Ständer
Förderung
- Deutsche Forschungsgemeinschaft
- Leo Pharma (Germany)
- LEO Pharma, the DFG Research Unit PruSearch FOR 2690
- DFG Research Unit SOMACROSS FOR5211
Zitieren
APA
Wiegmann, H., Renkhold, L., Zeidler, C., Agelopoulos, K., & Ständer, S. (2024). Interleukin Profiling in Atopic Dermatitis and Chronic Nodular Prurigo. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25158445
Vancouver
Wiegmann H, Renkhold L, Zeidler C, Agelopoulos K, Ständer S. Interleukin Profiling in Atopic Dermatitis and Chronic Nodular Prurigo. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25158445
BibTeX
@article{Wiegmann2024,
author = {Wiegmann, Henning and Renkhold, Lina and Zeidler, Claudia and Agelopoulos, Konstantin and Ständer, Sonja},
title = {Interleukin Profiling in Atopic Dermatitis and Chronic Nodular Prurigo},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25158445}
}
EUVIMED